Korea / Samsung Bioepis Goes Down Under; Blockchain-Based Vaccine Certificates; The First Korean Blockbuster?
The latest news from Korean pharma, including how Korea can put the infrastructure in place to develop a homegrown…
P&K Skin Research Center – South Korea
Last updated: 22.12.2014
Founded in November 2010, P&K Skin Research Center was established to provide scientific and systematic technical support and information according to various customers’ demands about clinical tests for developing new ingredients as well as functional cosmetics and quasi-drugs. P&K Skin Research Center started through a strategic alliance with Daebong LS Ltd, which is the only company manufacturing and selling pharmaceutical and cosmetic and healthy functional food ingredients, and Chung-ang University Research Center for Medical Scieces, which was the first research center to own a general hospital in Korea.
P&K Skin Research Center is equipped with facilities that meet not only the KFDA and EU guidelines but also US standards. Through analyzing all functional stroma and protocol from physical through to chemical inspection techniques for pharmaceutical ingredients, and through 30 years’ history of Daebong LS, we clinically test efficacy of general cosmetic and functional ingredients and cosmetics in accordance with KFDA, EU and US guidelines. Through these scientific evaluations, we are trying to provide scientific technical support and information for consumer satisfaction about products directly applied to the skin.
We do our utmost to ensure scientific validity, objectivity and also transparency for efficacy and functionality evaluation with Daebong LS, which has abundant clinical experiences at manufacturing and analysis, especially for pharmaceutical and cosmetic ingredients, and our experts include a dermatologist of a university hospital who has various clinical test experiences.
Contact details:
City B/D 2F, 118-2 Heukseok-dong, Dongjak-gu, Seoul 156-860 Korea
+82 2 6295 1501~3
Related
Joong Myung Cho – Chairman & CEO, CrystalGenomics, South Korea
Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery…
Young-Shik Cho – Chairman, SD Biosensor
Young-Shik Cho, chairman of SD Biosensor, recounts his journey leading diagnostics companies and expanding their…
Precision Medicine / Reclaiming Asia's Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome…
Jeong-Sun Seo – Chairman, Macrogen & President, KoreaBIO
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO),…
Sangrae Cho – CEO, Gencurix
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae…
Yeul-Hong Kim – Director, K-MASTER, South Korea
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data…
M&A / Korean Celltrion Makes First Big Global Move with Acquisition of Takeda APAC Assets
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the…
SCM Lifescience / A Global Approach to Korean Regenerative Medicine
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in…
Jisoo Pae – CEO, Genome & Company
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr…
Rare Diseases / Korean Corestem Targets US Market for Ground-Breaking ALS Treatment
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea,…
Kyung Suk Kim – CEO, Corestem
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic…
